GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (FRA:XP0) » Definitions » EV-to-EBITDA

Xenon Pharmaceuticals (FRA:XP0) EV-to-EBITDA : -5.46 (As of May. 31, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Xenon Pharmaceuticals's enterprise value is €1,469.70 Mil. Xenon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €-269.41 Mil. Therefore, Xenon Pharmaceuticals's EV-to-EBITDA for today is -5.46.

The historical rank and industry rank for Xenon Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

FRA:XP0' s EV-to-EBITDA Range Over the Past 10 Years
Min: -38   Med: -9.08   Max: 68.08
Current: -5.76

During the past 13 years, the highest EV-to-EBITDA of Xenon Pharmaceuticals was 68.08. The lowest was -38.00. And the median was -9.08.

FRA:XP0's EV-to-EBITDA is ranked worse than
100% of 497 companies
in the Biotechnology industry
Industry Median: 8.25 vs FRA:XP0: -5.76

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), Xenon Pharmaceuticals's stock price is €25.40. Xenon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-2.997. Therefore, Xenon Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Xenon Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Xenon Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals EV-to-EBITDA Chart

Xenon Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.32 -13.80 -14.77 -13.42 -8.59

Xenon Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.57 -9.55 -9.23 -8.59 -6.99

Competitive Comparison of Xenon Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Xenon Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's EV-to-EBITDA falls into.


;
;

Xenon Pharmaceuticals EV-to-EBITDA Calculation

Xenon Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1469.696/-269.411
=-5.46

Xenon Pharmaceuticals's current Enterprise Value is €1,469.70 Mil.
Xenon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-269.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenon Pharmaceuticals  (FRA:XP0) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Xenon Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=25.40/-2.997
=At Loss

Xenon Pharmaceuticals's share price for today is €25.40.
Xenon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.997.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Xenon Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Xenon Pharmaceuticals Headlines

No Headlines